Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.14 and traded as low as $0.5681. Galmed Pharmaceuticals shares last traded at $0.5710, with a volume of 29,593 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Galmed Pharmaceuticals presently has an average rating of “Reduce”.

Galmed Pharmaceuticals Stock Down 6.9%

The firm has a market capitalization of $3.13 million, a price-to-earnings ratio of -1.78 and a beta of 0.40. The business’s fifty day moving average is $0.80 and its 200 day moving average is $1.14.

Hedge Funds Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP acquired a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned about 1.28% of Galmed Pharmaceuticals as of its most recent SEC filing. 76.14% of the stock is owned by hedge funds and other institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.